Prognostic Value Of Sflc Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The Gmmg Mm5 Trial

Studies in newly diagnosed multiple myeloma (MM) described a prognostic value of the serum free light chain ratio (sFLCr) on progression free survival (PFS) and overall survival (OS). The GMMG MM5 phase III trial compares VCD (bortezomib, cyclophosphamide, dexamethasone) and PAd (bortezomib, adriamycin, dose-reduced dexamethasone) for induction therapy followed by stem cell mobilization and harvest, high-dose therapy and a lenalidomide-based consolidation/maintenance therapy for 2 years vs. lenalidomide until complete response (CR). First primary end point of the ongoing study was response after induction, second primary end point was progression-free survival. To analyse if the sFLCr has a prognostic value on the response after induction therapy with respect to achieve a very good partial response (VGPR) or better, we investigated patients with newly diagnosed MM which were included in the MM5 trial.